Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anthelminthic Agents

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

2-Amino-3,4-Dihydroquinazolines Exhibit Potent Antimalarial Activity by Targeting Plasmepsin X.

ACS infectious diseases·2026

Same author

Plasmepsins as Antimalarial Drug Targets-Then, Now, and the Future.

Medicinal research reviews·2026

Same author

Discovery of MK-5661, a Once-Daily Oral Na<sub>V</sub>1.8 Inhibitor for the Treatment of Pain.

ACS medicinal chemistry letters·2026

Same author

Artemether-lumefantrine for the treatment of Plasmodium falciparum malaria in Laos: a therapeutic efficacy study coupled with genomic and in vitro phenotypic analyses.

The Lancet. Microbe·2026

Same author

Unpacking boxes: identification of novel inhibitors of malaria parasite invasion.

International journal for parasitology. Drugs and drug resistance·2026

Same author

A unique transcriptomic landscape defines African-specific grade group 1 prostate cancer.

Research square·2026

Search research articles

Related Experiment Video

Updated: May 11, 2026

A Multi-detection Assay for Malaria Transmitting Mosquitoes

A Multi-detection Assay for Malaria Transmitting Mosquitoes

Published on: February 28, 2015

MK-7602: a potent multi-stage dual-targeting antimalarial.

Paola Favuzza¹, Josephine Palandri¹, Manuel de Lera Ruiz²

¹The Walter and Eliza Hall Institute of Medical Research, Parkville, 3052, Australia; University of Melbourne, Melbourne, 3010, Australia.

|December 7, 2025

Summary

A new antimalarial drug, MK-7602, effectively targets malaria parasites by inhibiting plasmepsins IX and X. This novel compound shows promise against drug-resistant malaria strains and has a high barrier to resistance development.

Keywords:

Antimalarial drug Aspartic proteases Falciparum Malaria Plasmepsin Vivax

More Related Videos

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors

Published on: May 12, 2022

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

Related Experiment Videos

Last Updated: May 11, 2026

A Multi-detection Assay for Malaria Transmitting Mosquitoes

A Multi-detection Assay for Malaria Transmitting Mosquitoes

Published on: February 28, 2015

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors

Published on: May 12, 2022

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

Area of Science:

Medicinal Chemistry
Parasitology
Drug Discovery

Background:

Substantial global malaria burden necessitates novel antimalarials due to increasing parasite resistance.
Existing treatments face challenges from drug-resistant malaria strains, demanding new mechanisms of action.

Purpose of the Study:

To develop and characterize a novel antimalarial compound targeting Plasmodium aspartic proteases.
To evaluate the efficacy and resistance profile of the new compound, MK-7602.

Main Methods:

High-throughput screening and medicinal chemistry optimization were employed.
In vitro and in vivo testing were conducted to assess MK-7602's antimalarial activity.
MK-7602 was evaluated as a dual inhibitor of plasmepsins IX and X.

Main Results:

MK-7602 is a dual sub-nanomolar inhibitor of plasmepsins IX and X across multiple Plasmodium species.
The compound demonstrated activity against liver and blood stages, blocked parasite transmission, and possessed favorable pharmacokinetics and safety.
MK-7602 exhibited a high barrier to resistance and lacked cross-resistance with existing antimalarial-resistant strains.

Conclusions:

MK-7602 represents a new class of antimalarial with a novel mechanism, offering potential for treating uncomplicated and drug-resistant malaria.
Clinical evaluation of MK-7602 against Plasmodium falciparum is currently underway.